Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials

A Amstutz, B Speich, F Mentré, CS Rueegg… - The Lancet …, 2023 - thelancet.com
Background Interpretation of the evidence from randomised controlled trials (RCTs) of
remdesivir in patients treated in hospital for COVID-19 is conflicting. We aimed to assess the …

[HTML][HTML] The journey of remdesivir: from Ebola to COVID-19

J Pardo, AM Shukla, G Chamarthi, A Gupte - Drugs in context, 2020 - ncbi.nlm.nih.gov
Countries around the world are currently fighting the coronavirus disease 2019 (COVID-19)
pandemic, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV …

Drug treatment of COVID-19 infection

G Lui, G Guaraldi - Current opinion in pulmonary medicine, 2023 - journals.lww.com
Drug treatment of COVID-19 infection : Current Opinion in Pulmonary Medicine Drug treatment
of COVID-19 infection : Current Opinion in Pulmonary Medicine Log in or Register Subscribe to …

[HTML][HTML] Methods for living guidelines: early guidance based on practical experience. Paper 5: decisions on methods for evidence synthesis and recommendation …

DF Navarro, S Cheyne, K Hill, E McFarlane… - Journal of clinical …, 2023 - Elsevier
Objectives Producing living guidelines requires making important decisions about methods
for evidence identification, appraisal, and integration to allow the living mode to function …

Remdesivir alone or in combination with monoclonal antibodies as an early treatment to prevent severe COVID-19 in patients with mild/moderate disease at high risk …

R Scotto, AR Buonomo, A Iuliano, M Foggia… - Vaccines, 2023 - mdpi.com
Early treatment with antivirals against SARS-CoV-2 infection can prevent the onset of severe
COVID-19 in fragile and immunocompromised patients. In this real-life, prospective …

Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis

L Di Stefano, EL Ogburn, M Ram, DO Scharfstein, T Li… - PloS one, 2022 - journals.plos.org
Background Results from observational studies and randomized clinical trials (RCTs) have
led to the consensus that hydroxychloroquine (HCQ) and chloroquine (CQ) are not effective …

COVID-19 therapies for inpatients: a review and quality assessment of clinical guidelines

DA Wohl, AA Espinueva, L Dau, CY Wang… - ERJ Open …, 2022 - Eur Respiratory Soc
Owing to condensed development processes, expanding evidence and differences in
healthcare system characteristics, many COVID-19 guidelines differ in their quality and …

Your Outpatient has Coronavirus Disease 2019: What Are the Treatment Options in the Current Severe Acute Respiratory Syndrome Coronavirus 2 Variant Climate?

WA Werbel, ED Weld, SD Advani… - Clinical Infectious …, 2023 - academic.oup.com
Mutations accumulated by novel Severe Acute Respiratory Syndrome Coronavirus 2
Omicron sublineages contribute to evasion of previously effective monoclonal antibodies for …

Optimal duration of systemic corticosteroids in Coronavirus Disease 2019 treatment: a systematic review and meta-analysis

P Ssentongo, N Yu, N Voleti, S Reddy… - Open Forum …, 2023 - academic.oup.com
Background Corticosteroids confer a survival benefit in individuals hospitalized with
coronavirus disease 2019 (COVID-19) who require oxygen. This meta-analysis seeks to …

Use of Systemic Antibiotics in Patients with COVID-19 in Colombia: A Cross-Sectional Study

LF Valladales-Restrepo, AC Delgado-Araujo… - Antibiotics, 2023 - mdpi.com
Antibiotics are frequently prescribed to patients with COVID-19. The aim was to determine
the pattern of use of systemic antibiotics in a group of patients diagnosed with COVID-19 in …